Results of a phase II study examining camrelizumab and decitabine for treatment of relpased Hodgkin lymphoma.
Home / Resource Library / Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma